Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

DISEASE CHARACTERISTICS: Proven or probable invasive aspergillosis or other filamentous fungal infection by cytology, histopathology, or culture within the past 7 days Presenting with 1 of the following: Cancer Aplastic anemia Inherited immunodeficiencies Autoimmune deficiency disorders Acquired immunodeficiencies Recipient of autologous peripheral blood stem cell or bone marrow transplantation CNS aspergillosis or other filamentous fungal infection allowed No invasive zygomycosis infection PATIENT CHARACTERISTICS: Age 2 and over Performance status Not specified Life expectancy At least 7 days Hematopoietic Not specified Hepatic ALT no greater than 5 times upper limit of normal Renal Creatinine clearance at least 30 mL/min Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception No prior significant CNS disorder (e.g., multiple sclerosis or uncontrolled seizures) No prior grade 3 or 4 toxicity or severe allergic reaction to interferon gamma No prior intolerance or hypersensitivity to voriconazole or other azoles No acute or chronic graft-versus-host disease No conditions that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy See Disease Characteristics No prior allogeneic peripheral blood or bone marrow transplantation No concurrent interferon alfa Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery No prior solid organ transplantation Other Prior voriconazole allowed At least 24 hours since prior administration of any of the following: Astemizole Cisapride Pimozide Quinidine Sirolimus Terfenadine Rifabutin Ergot alkaloids Sildenafil citrate Amiodarone Flecainide Systemic lidocaine More than 14 days since prior long-acting barbiturates, carbamazepine, or rifampin No other concurrent systemic antifungal drugs No other concurrent investigational agents